Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naive or experienced patients.

Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naive or experienced patients. Meeting Abstract

publication date

February 1, 2018

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

volume

36

issue

4